Cancer therapy with a parvovirus combined with bevacizumab

Abstract

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

1 . Pharmaceutical composition containing (a) a parvovirus in combination with (b) bevazizumab, wherein said parvovirus is 5 H-1 (H-IPV). 
     
     
         2 . The pharmaceutical composition of  claim 1  containing (a) the parvovirus and (b) bevacizumab, wherein the parvovirus is formulated for intratumoral or intravenous administration, and 10 bevacizumab is formulated for intravenous administration. 
     
     
         3 . The pharmaceutical composition as defined in  claim 1  for use in a method of treating cancer. 
     
     
         4 . The pharmaceutical composition for the use according to  claim 3  characterized in that the parvovirus and bevacizumab are sequentially administered. 
     
     
         5 . The pharmaceutical composition for the use according to  claim 3  characterized in that the use is for treating solid tumours and/or cancer initiating stem cells. 
     
     
         6 . The pharmaceutical composition for the use according to of  claim 3  characterized in that the use is for treating 25 tumours resistant to parvovirus cytotoxicity. 
     
     
         7 . The pharmaceutical composition for use according to  claim 3 , wherein the tumour is a brain tumour, pancreatic carcinoma, cervical carcinoma, lung cancer, head 30 and neck cancer, breast cancer or colon cancer. 
     
     
         8 . The pharmaceutical composition for the use according to  claim 3  characterized in that the use is for treating a glioma or recurrent glioblastoma multiforme.